{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=9", "query": { "condition": "Relapsed/Refractory", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 3665, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T22:22:25.933Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03077828", "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphocyte-Rich Classical Hodgkin Lymphoma", "Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Recurrent Mixed Cellularity Classical Hodgkin Lymphoma", "Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma", "Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Refractory Mixed Cellularity Classical Hodgkin Lymphoma", "Refractory Nodular Sclerosis Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-04-21", "completion_date": "2024-12", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03077828" }, { "nct_id": "NCT00012181", "title": "Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Retinoblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 30, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012181" }, { "nct_id": "NCT00562965", "title": "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "inotuzumab ozogamicin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone/prednisolone", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-11", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 17, "location_summary": "Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more", "locations": [ { "city": "Mission Hills", "state": "California" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Novi", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562965" }, { "nct_id": "NCT04544592", "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia", "B-cell Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "31 Days", "maximum_age": "30 Years", "sex": "ALL", "summary": "31 Days to 30 Years" }, "enrollment_count": 45, "start_date": "2021-03-10", "completion_date": "2031-03-10", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544592" }, { "nct_id": "NCT00710528", "title": "Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Lymphoma, Non-Hodgkin (NHL)", "Acute Myeloid Leukemia (AML)", "Multiple Myeloma (MM)" ], "interventions": [ { "name": "CAL-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2008-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-08-31", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 9, "location_summary": "Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00710528" }, { "nct_id": "NCT02464228", "title": "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2016-02-25", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 5, "location_summary": "Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464228" }, { "nct_id": "NCT04809467", "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "tafasitamab", "type": "DRUG" }, { "name": "parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-16", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04809467" }, { "nct_id": "NCT02992522", "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma, Unspecified", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Transformed Recurrent Non-Hodgkin Lymphoma", "B-Cell" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Beth Christian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2017-02-21", "completion_date": "2027-04-15", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Columbus, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02992522" }, { "nct_id": "NCT00891137", "title": "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma", "Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "human myeloid progenitor cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cellerant Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-10-27", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 8, "location_summary": "Orange, California • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891137" }, { "nct_id": "NCT00461045", "title": "Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "MRZ 0.5 mg/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2007-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-12-19", "last_synced_at": "2026-11-12T22:22:25.933Z", "location_count": 6, "location_summary": "Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00461045" } ] }